Comedian Reggie Watts Faces Scrutiny Over Ketamine Advocacy
AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.
You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.
Comedian Reggie Watts Faces Scrutiny Over Ketamine Advocacy
- Comedian Reggie Watts is facing allegations from former partners and friends of his late ex-girlfriend, Katherine Early McCollough, who claim his advocacy for ketamine contributed to her addiction and eventual death by suicide.
- Watts' team has denied these claims, calling them "dangerously false," following McCollough's death in Lima, Peru, in April 2026.
Full Summary — powered by AI
Reggie Watts, known for his comedic and musical work, has publicly advocated for the use of ketamine and other psychedelics, promoting them as tools for exploring consciousness. However, this advocacy has drawn criticism after the death of his ex-girlfriend, Katherine Early McCollough, in April 2026.
Friends and former partners of McCollough have come forward, alleging that Watts’ encouragement of ketamine use fueled her addiction, which they claim ultimately led to her death by suicide. Watts’ representatives have strongly refuted these accusations, labeling them as “dangerously false.”
Katherine Early McCollough was an event and comedy producer who had been in a relationship with Watts for over a year. She passed away in Lima, Peru, where she was traveling. Following her death, Watts posted a tribute on Instagram, expressing his grief and acknowledging that McCollough “was in pain.” A GoFundMe campaign was initiated by McCollough’s loved ones to help her family with the costs of transporting her remains back to South Carolina, raising over $30,000.
Ketamine, originally an anesthetic, has gained attention in recent years for its potential in treating mental health conditions such as depression, anxiety, and PTSD. The FDA approved a ketamine-derived therapy for treatment-resistant depression in 2019. While it can offer rapid relief for some, particularly in cases of suicidal ideation, medical professionals emphasize that ketamine therapy should be administered by trained healthcare providers due to potential side effects like psychedelic symptoms, cardiovascular stimulation, and the risk of misuse or addiction, especially with frequent recreational use. The American Society of Anesthesiologists released guidance in February 2025 stressing the importance of professional supervision and monitoring during ketamine treatment.